Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Centrexion Therapeutics

Status and phase: Completed; Phase 2

Conditions: Osteoarthritis

Treatments: Drug: CNTX-4975; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02558439

4975-OA-502

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of a single injection of CNTX-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain.

Enrollment: 175 patients

Sex: All

Ages: 45 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Radiography of both knees with a posterior-anterior, fixed flexion view taken during the Screening period. The index knee must show evidence of chronic OA.
• Moderate to severe pain in the index knee associated with OA must be stable for a minimum of 2 months prior to Screening, as assessed by the Investigator.
• A specified mean pain score in the index knee over the 7 days prior to dosing, based on question A1 of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC A1).
• Specified baseline and screening scores on the WOMAC A1
• Body Mass Index ≤ 45 kg/m2.
• Subjects must have had a therapeutic failure (no relief, or inadequate relief), and/or AEs resulting in stopping treatment, and/or contraindication to the standard of care appropriate to the severity of the index knee OA pain they are experiencing.

Exclusion criteria

• Joint replacement surgery of the index knee at any time, or open surgery of the index knee in the past 12 months.

• Prior arthroscopic surgery of the index knee within 3 months of Screening.

• Any painful conditions of the index knee due to joint disease other than OA.

• Mild pain in the non-index knee when walking.

• Other chronic pain anywhere in the body that requires the use of analgesic medications.

• Secondary OA of the index knee due to acute traumatic injury.

• Significant current or past instability (e.g., cruciate ligament tear or rupture or previous repair) or misalignment (> 10 degrees varus or valgus) of the index knee

• Has used topical capsaicin on the index knee within 90 days of Screening.

• Corticosteroid injection in the index knee within 90 days of Screening.

• Received IA viscosupplementation (e.g., Synvisc®, Hyalgan®) within 90 days of Screening.

• Prior participation in an ALGRX 4975 or CNTX-4975 study.

• Has any of the following characteristics:

  1. active or historic substance use disorder within the previous year as defined by the Diagnostic and Statistical Manual for Mental Health Disorders, fifth edition, or
  2. tests positive upon urine drug screen for a substance of abuse.

• Has moderate to severe depression or anxiety.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

175 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.

Treatment:

Other: Placebo

0.5 mg CNTX-4975

Experimental group

Description:

Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.

Treatment:

Drug: CNTX-4975

1.0 mg CNTX-4975

Experimental group

Description:

Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.

Treatment:

Drug: CNTX-4975